Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2009-10-01 Share Issue/Capital Cha…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Share Purchase Plan $7.0 million raising 1 page ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Phosphagenics Limited regarding the completion and results of a Share Purchase Plan (SPP). It details the number of shares issued, the issue price, underwriting information, and key future dates related to the allotment and trading of the new shares. There are no financial statements or detailed financial analysis present, and the document is relatively short (1912 characters). This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2009-10-01 English
Share Purchase Plan Issue Price 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 25 September 2009 regarding the Share Purchase Plan (SPP) issue price. It specifies the discounted issue price for shares under the plan, key dates for allotment, trading, and despatch of statements. The content focuses on financing activity related to share issuance rather than a full financial report or other types of filings. The document length is short (833 characters), and it is clearly an update on capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP).
2009-09-24 English
Transdermal Oxycodone Matrix Patch Phase 1 Trial 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 15 September 2009 about the successful completion of a Phase 1 clinical trial for a transdermal oxycodone matrix patch. It discusses trial results, drug delivery, and future plans for further trials. There are no financial statements, regulatory filings, or detailed financial data. The content is primarily a clinical trial update and product development news rather than a financial report or regulatory filing. It is not an earnings release, annual report, or interim report. The document is a corporate announcement about a clinical trial milestone, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2009-09-14 English
POH to Commence Phase 2-3 Topical Diclofenac Trial 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a press release dated 9 September 2009 from Phosphagenics announcing the commencement of a Phase 2/3 clinical trial for a topical diclofenac drug delivery system. It discusses trial results from a Phase 1B study and plans for future clinical trials and regulatory filings (IND submission to the FDA). The content is focused on clinical trial progress and product development updates rather than financial results, regulatory filings, or shareholder information. It does not contain financial statements, earnings data, or governance information. It is an announcement of a clinical trial commencement and related research progress, which fits best under a general regulatory or corporate announcement category rather than a financial or governance report. Given the absence of a more specific category for clinical trial announcements, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2009-09-08 English
Share Purchase Plan documentation and Newsletter 17 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a detailed Share Purchase Plan (SPP) announcement and application form from Phosphagenics Limited dated 25 August 2009. It includes terms and conditions, eligibility criteria, payment instructions, and key dates related to the share purchase plan offering to shareholders. The content focuses on informing shareholders about the opportunity to purchase new shares, the process to apply, and the legal and procedural framework governing the plan. There are no financial statements, earnings data, management discussion, or audit information present. The document is not a report but an announcement and offering document related to capital raising through a share purchase plan. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2009-08-24 English
June 2009 Half Yearly Appendix 4D and Financial Report 28 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half Year Report for the period ended 30 June 2009' and includes detailed financial information such as the Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flow, and Notes to the Financial Statements. It also contains a Directors' Report and an Independent Auditor's Report. The document covers a half-year period and provides substantive financial data and analysis, consistent with an Interim / Quarterly Report. The presence of the Appendix 4D form, which is an Australian Securities Exchange (ASX) requirement for half-year financial reporting, further confirms this classification. The document is not a brief announcement or a certification but a full financial report for the half-year period. H1 2009
2009-08-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.